サンプル依頼リスト カート
  • English
  • Korean
表紙：慢性炎症治療の世界市場-2023年～2030年
市場調査レポート
商品コード
1352119

慢性炎症治療の世界市場-2023年～2030年

Global Chronic Inflammation Treatment Market - 2023-2030
出版日: | 発行: DataM Intelligence | ページ情報: 英文 195 Pages | 納期: 約2営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.90円
慢性炎症治療の世界市場-2023年～2030年
出版日: 2023年09月27日
発行: DataM Intelligence
ページ情報: 英文 195 Pages
納期: 約2営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

概要

慢性炎症治療の市場動向は、技術的進歩の高まりにより製品の発売が増加していることを示しています。数ヶ月から数年続く炎症は慢性炎症治療として知られています。慢性炎症治療の強度と効果の主な決定要因は、外傷の原因と、損傷を修復して元に戻す身体の能力です。

さらに、検査や薬の利用可能性の上昇や市場における非特異的増殖性慢性炎症治療の数の増加による慢性炎症治療のための製品の採用の上昇、および研究開発の増加が慢性炎症治療の市場規模を押し上げています。

市場は、この分野での進歩の高まりの結果として、北米地域からの製品に対する需要の伸びを経験しています。Pfizer Inc.、NodThera、Abcentra、Halia Therapeutics, Inc.などの主要な競合企業が積極的に市場に参入しています。

ダイナミクス

主要企業による進歩と臨床試験の増加が慢性炎症治療市場の成長を牽引

慢性炎症性疾患は、特に欧米先進国において、過去数十年の間に発生率と有病率が増加しています。炎症と痛みを軽減するために、いくつかの非ステロイド性抗炎症薬（NSAID）が利用されていますが、副作用が無いか僅かな植物性の自然薬品と異なり、これらの抗炎症薬にはさまざまな深刻な副作用があります。

ナノ粒子は、薬物充填能力が高く、特定の細胞や組織に対する標的選択性が高い可能性があるため、治療薬としてのバイオアベイラビリティを高め、薬物動態および薬力学（PKPD）を改善する可能性のある、新しいタイプの薬剤送達システムです。前述のような主張の結果として、予測期間を通じて市場は主導権を握ると予測されます。

研究開発と新製品上市の増加が市場成長の機会を生み出す

長年の研究の結果、現在では多くの大手メーカーが新規製品を開発し、治療目的で発売しており、これが慢性炎症治療市場の拡大を促進しています。いくつかの治療薬は、慢性炎症の管理薬として規制当局から承認されています。

例えば、2021年2月12日、末梢神経を侵す慢性炎症性脱髄性多発ニューロパチー（CIDP）として知られる珍しい神経疾患の成人患者を治療するためのPANZYGA-ifas 10%液剤の生物製剤追加承認申請が米国食品医薬品局（FDA）により承認されました。患者の臨床ニーズにより応えるため、パンジーガは、CIDPに対する2種類の維持用量をFDAが承認した唯一の静注用免疫グロブリン製剤（IVIg）です。

慢性炎症治療薬の副作用が市場の成長を妨げる

慢性炎症治療薬にはいくつかの副作用があり、市場の成長を抑制する可能性があります。最も一般的な消化器系の副作用は腹痛、吐き気、下痢で、患者の20～30%が経験し、自然に治ることが多いです。乳酸アシドーシスはより重篤な副作用で、毎年10万人あたり1.5人程度にしか生じません。

メトホルミンは一般的に安全であると考えられていますが、乳酸アシドーシスという重大な副作用があります。この病気は、血液中に筋肉や赤血球が産生する化学物質である乳酸が過剰に含まれると発症します。通常、乳酸レベルは低いです。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • 主要企業による進歩と臨床試験の増加
      • 慢性炎症性疾患の増加
    • 抑制要因
      • 慢性炎症治療薬の副作用
    • 機会
      • 研究開発と新製品上市の増加
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 価格分析
  • 規制分析
  • パイプライン分析
  • 特許分析
  • SWOT分析

第6章 COVID-19分析

第7章 種類別

  • 非特異的増殖性
  • 肉芽腫性炎症
    • 異物肉芽腫
    • 感染性肉芽腫

第8章 薬剤別

  • メトホルミン
  • 非ステロイド性抗炎症薬（NSAID）
    • ナプロキセン
    • イブプロフェン
    • アスピリン
  • スタチン
    • シンバスタチン
    • ロスバスタチン
  • コルチコステロイド
    • コルチゾン
    • プレドニン
  • ハーブサプリメント

第9章 慢性炎症性の疾患の種類別

  • 糖尿病
  • 心血管疾患
  • 関節炎および関節疾患
  • 慢性閉塞性肺疾患（COPD）
  • アレルギー
  • その他

第10章 流通チャネル別

  • 病院薬局
  • 小売薬局
  • オンライン薬局

第11章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • スペイン
    • イタリア
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋
  • 中東・アフリカ

第12章 競合情勢

  • 競合シナリオ
  • 市況/シェア分析
  • M&A分析

第13章 企業プロファイル

  • Pfizer Inc.
    • 企業概要
    • 製品ポートフォリオと説明
    • 財務概要
    • 主な動向
  • NodThera
  • Abcentra
  • Evommune, Inc.
  • Sterna biologicals
  • Halia Therapeutics, Inc.
  • Amgen Inc.
  • AstraZeneca
  • Takeda Pharmaceutical Company Limited
  • Annexon, Inc.

第14章 付録

目次
Product Code: PH6879

Overview

The chronic inflammation treatment market trends show rising product launches owing to the rising technological advancements. Inflammation that lasts for a few months to years is known as chronic inflammation treatment. The cause of the trauma and the ability of the body to repair and undo the harm are the main determinants of the intensity and effects of chronic inflammation treatment.

Furthermore, rising adoption of products for chronic inflammation treatment due to the rising availability of tests or medications and increase in the number of nonspecific proliferative chronic inflammation treatment in the market, and an increase in the research and development is driving up the chronic inflammation treatment market size.

The market is experiencing a growth demand for products from North American areas as a result of the rising advancements in this field. With significant competitors like Pfizer Inc., NodThera, Abcentra, and Halia Therapeutics, Inc. actively operating in the market.

Dynamics

Growing Advancements and Clinical Trials by Key Players Drive the Growth of the Chronic Inflammation Treatment Market

Chronic inflammatory illnesses have increased in incidence and prevalence during the past few decades, particularly in Westernized nations. In order to reduce inflammation and pain, several NSAIDs are utilized; however, these anti-inflammatory drugs have a wide range of severe side effects, as opposed to plant-based natural medicines, which have anti-inflammatory medicinal properties with few to no negative side effects.

With their high drug loading capacity and potential for good target selectivity for specific cells and tissues, nanoparticles are a novel type of drug delivery system that may enhance therapeutic bioavailability and improve pharmacokinetics and pharmacodynamics (PKPD). The market is predicted to take the lead throughout the forecast period as a consequence of the aforementioned claims.

Rising Research and Development and Novel Product Launches Creates Opportunities for the Growth of the Market

As a result of years of study, a number of major manufacturers are now developing novel products and releasing them for therapeutic purposes, which is fostering the expansion of the chronic inflammation treatment market. Several treatments have been approved by the regulatory authorities for management of chronic inflammation.

For instance, on February 12, 2021, the supplemental Biologics License Application for PANZYGA - ifas 10% Liquid Preparation to treat adult patients with the uncommon neurological condition known as chronic inflammatory demyelinating polyneuropathy (CIDP), which affects the peripheral nerves, was approved by the U.S. Food and Drug Administration (FDA). In order to better serve patients' clinical needs, PANZYGA is the one and only intravenous immunoglobulin (IVIg) that has two FDA-approved maintenance dosage alternatives for CIDP.

Side Effects of Chronic Inflammation Treatment Medications will hamper the growth of the market

Several side effects are linked with the chronic inflammation treatment medications which can restrain the market's growth. The most common gastrointestinal adverse effects are abdominal pain, nausea, and diarrhea, which are experienced by 20% to 30% of patients and frequently go away on their own. Lactic acidosis is a more serious consequence that only occurs in about 1.5 per 100,000 persons each year.

Although metformin is generally thought to be rather safe, it does have one major (though uncommon) side effect known as lactic acidosis. This illness develops when the blood contains an excessive amount of lactate, a chemical produced by the muscles and red blood cells. Your lactic acid level is typically low.

For more details on this report - Request for Sample

Segment Analysis

The global chronic inflammation treatment market is segmented based type, medications, chronic inflammatory disease type, distribution channel and region.

Owing to High Demand, the Metaformin from Medication Segment Accounted for Approximately 37.1% of the Chronic Inflammation Treatment Market Share

The metaformin category from medications held the largest market share in 2022 and is expected to maintain its dominance over the forecast period due to a growth in inflammatory disorders worldwide. Throughout the world, the biguanide metformin acts as the first-line pharmaceutical treatment for type II diabetic mellitus (T2D).

Metformin is the most adaptable and therapeutically significant medication to date. The glycemic control brought on by the reduction of hepatic glucose output, the suppression of autoimmune inflammation by controlling T-cell balance, the decrease of cardiovascular mortality, the prevention of cancer, and dementia are just a few of the most significant therapeutic benefits of metformin.

Since metformin has been shown to reduce inflammation, it is a desirable medicine to test for a variety of different disorders. Additionally, leukocytes from PCOS participants with lower amounts of reactive oxygen species, TNF and IL-6 and higher levels of glutathione were found. Recent research demonstrates that metformin has an instant anti-inflammatory effect in addition to reducing Chronic Inflammation Treatment by enhancing metabolic parameters.

Geographical Penetration

North America Accounted for Approximately 42.3% of the Market Share in 2022, Owing to the Strong Presence of Major Players and Increasing Healthcare Infrastructure Investment

Due to the rising need for chronic inflammation treatment in healthcare, manufacturers in North America have chances of increasing their operations. There are many producers and suppliers in North America and owing to the quick economic growth of the region, industrial production has expanded, driving the demand for chronic inflammation treatment.

Increasing expenditure on healthcare and rising adoption among patients, advancement of technologies for medications, and increase in pharmaceutical business establishment across the region are also contributing to the growth of chronic inflammation treatment market share of this region.

It is also anticipated that the main healthcare organizations' and enterprises' collaborative research projects as well as new product development, which constantly seeks to improve available simulation training alternatives, will contribute to the expanding demand. Individuals are becoming more aware of various advanced chronic inflammatory disorders and their medications that are being utilized for treatment purposes, leading to the expansion of the market in this region. The above-mentioned factors further proves the dominance of North America on a global scale.

Competitive Landscape

The major global players in the chronic inflammation treatment market include Pfizer Inc., NodThera, Abcentra, Evommune, Inc., Sterna biologicals, Halia Therapeutics, Inc., Amgen Inc., AstraZeneca, Takeda Pharmaceutical Company Limited and Annexon, Inc. among others.

COVID-19 Impact Analysis

Russia Ukraine Conflict Analysis

Due to the low prevalence as well as absence of major market participants in this region, it is predicted that the Russia-Ukraine conflict will not have a significant effect on the worldwide chronic inflammation treatment market. The growth of the global chronic inflammation treatment market, however, is anticipated to be relatively unaffected by the import and export of raw materials over the forecast period.

By Type

  • Nonspecific Proliferative
  • Granulomatous Inflammation
  • Foreign Body Granuloma
  • Infectious Granuloma

By Medications

  • Metformin
  • Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
  • Naproxen
  • Ibuprofen
  • Aspirin
  • Statins
    • Simvastatin
    • Rosuvastatin
  • Corticosteroids
    • Cortisone
    • Prednisone
  • Herbal Supplements

By Chronic Inflammation Disease Type

  • Diabetes
  • Cardiovascular Diseases
  • Arthritis and Joint Diseases
  • Chronic Obstructive Pulmonary Disease (COPD)
  • Allergies
  • Others

By Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Rest of Europe
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • Rest of Asia-Pacific
  • Middle East and Africa

Key Developments

  • On August 7, 2023, the enrollment of participants in the Phase I study (NCT05447546) assessing HT-6184, Halia Therapeutics' lead asset, for chronic inflammation treatment has been completed, according to the company, which is developing novel medications to treat a wide range of diseases caused by Chronic Inflammation Treatment. The NLRP3 inflammasome activity is inhibited by the first pharmacological candidate, HT-6184, which targets the protein NEK7 via an allosteric mechanism.
  • On April 26,, 2023, a $50 million Series B round of financing for the clinical-stage biotechnology startup Evommune, Inc.'s research and development of novel therapies for inflammatory illnesses. Arix Bioscience, a new investor, along with EQT Life Sciences, SymBiosis, and several current investors co-led the fundraising. Several participants included Amplitude Ventures, another new investor, as well as Series A investors Andera Partners and Pivotal bioVenture Partners.
  • On June 20, 2023, HYQVIA (Recombinant Human Hyaluronidase with Immune Globulin Infusion 10%) was studied as a maintenance therapy in older individuals with chronic inflammatory demyelinating polyneuropathy (CIDP), and Takeda released the entire results of the pivotal Phase 3 ADVANCE-CIDP 1 clinical trial. When HYQVIA was compared to placebo, the results revealed a clinically significant decrease in the relapse rate, and additional study revealed a prolonged time until recurrence.

Why Purchase the Report?

  • To visualize the global chronic inflammation treatment market segmentation based on type, medications, chronic inflammatory disease type, distribution channel and region, as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of chronic inflammation treatment market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as excel consisting of key products of all the major players.

The global chronic inflammation treatment market report would provide approximately 69 tables, 71 figures and 195 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Type
  • 3.2. Snippet by Medications
  • 3.3. Snippet by Chronic Inflammatory Disease Type
  • 3.4. Snippet by Distribution Channel
  • 3.5. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Growing advancements and clinical trials by key players
      • 4.1.1.2. Rising chronic inflammation diseases prevalence
    • 4.1.2. Restraints
      • 4.1.2.1. Side effects of chronic inflammation treatment medications
    • 4.1.3. Opportunity
      • 4.1.3.1. Rising research and development and novel product launches
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Pipeline Anbalysis
  • 5.6. Patent Analysis
  • 5.7. SWOT Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID-19
    • 6.1.2. Scenario During COVID-19
    • 6.1.3. Scenario Post COVID-19
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 7.1.2. Market Attractiveness Index, By Type
  • 7.2. Nonspecific Proliferative *
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Granulomatous Inflammation
    • 7.3.1. Foreign Body Granuloma
    • 7.3.2. Infectious Granuloma

8. By Medications

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medications
    • 8.1.2. Market Attractiveness Index, By Medications
  • 8.2. Metformin *
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Non-steroidal anti-inflammatory drugs (NSAIDs)
    • 8.3.1. Naproxen
    • 8.3.2. Ibuprofen
    • 8.3.3. Aspirin
  • 8.4. Statins
    • 8.4.1. Simvastatin
    • 8.4.2. Rosuvastatin
  • 8.5. Corticosteroids
    • 8.5.1. Cortisone
    • 8.5.2. Prednisone
  • 8.6. Herbal Supplements

9. By Chronic Inflammatory Disease Type

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Chronic Inflammatory Diseases
    • 9.1.2. Market Attractiveness Index, By Chronic Inflammatory Diseases
  • 9.2. Diabetes *
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Cardiovascular Diseases
  • 9.4. Arthritis and Joint Diseases
  • 9.5. Chronic Obstructive Pulmonary Disease (COPD)
  • 9.6. Allergies
  • 9.7. Others

10. By Distribution Channel

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.1.2. Market Attractiveness Index, By Distribution Channel
  • 10.2. Hospital Pharmacy *
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 10.3. Retail Pharmacy
  • 10.4. Online Pharmacy

11. By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medications
    • 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Chronic Inflammatory Diseases
    • 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.2.7.1. U.S.
      • 11.2.7.2. Canada
      • 11.2.7.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medications
    • 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Chronic Inflammatory Diseases
    • 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.3.7.1. Germany
      • 11.3.7.2. U.K.
      • 11.3.7.3. France
      • 11.3.7.4. Spain
      • 11.3.7.5. Italy
      • 11.3.7.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 12.4.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 12.4.2. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medications
    • 12.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Chronic Inflammatory Diseases
    • 12.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 12.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 12.4.5.1. Brazil
      • 12.4.5.2. Argentina
      • 12.4.5.3. Rest of South America
  • 11.5. Asia-Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medications
    • 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Chronic Inflammatory Diseases
    • 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.5.7.1. China
      • 11.5.7.2. India
      • 11.5.7.3. Japan
      • 11.5.7.4. Australia
      • 11.5.7.5. Rest of Asia-Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medications
    • 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Chronic Inflammatory Diseases
    • 11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

12. Competitive Landscape

  • 12.1. Competitive Scenario
  • 12.2. Market Positioning/Share Analysis
  • 12.3. Mergers and Acquisitions Analysis

13. Company Profiles

  • 13.1. Pfizer Inc. *
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Financial Overview
    • 13.1.4. Key Developments
  • 13.2. NodThera
  • 13.3. Abcentra
  • 13.4. Evommune, Inc.
  • 13.5. Sterna biologicals
  • 13.6. Halia Therapeutics, Inc.
  • 13.7. Amgen Inc.
  • 13.8. AstraZeneca
  • 13.9. Takeda Pharmaceutical Company Limited
  • 13.10. Annexon, Inc.

LIST NOT EXHAUSTIVE

14. Appendix

  • 14.1. About Us and Services
  • 14.2. Contact Us